Losartan for Arthrofibrosis

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Arthrofibrosis
Losartan - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether losartan can reduce scar tissue formation and improve range of motion following surgery.

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Arthrofibrosis

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 90 days post-surgery

90 days post-surgery
Post-Operative Range of Motion (ROM)
Post-Operative Rate of Manipulation under Anesthesia (MUA)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Arthrofibrosis

Side Effects for

Usual Treatment
22%Laboratory values outside normal range
19%Psychiatric Hospitalization
7%Medical Hospitalization
2%Completed suicide
1%Diabetes
1%Suicide attempt
This histogram enumerates side effects from a completed 2021 Phase 4 trial (NCT02188121) in the Usual Treatment ARM group. Side effects include: Laboratory values outside normal range with 22%, Psychiatric Hospitalization with 19%, Medical Hospitalization with 7%, Completed suicide with 2%, Diabetes with 1%.

Trial Design

2 Treatment Groups

Control Group
1 of 2
Losartan Group
1 of 2
Active Control
Experimental Treatment

380 Total Participants · 2 Treatment Groups

Primary Treatment: Losartan · No Placebo Group · Phase 4

Losartan Group
Drug
Experimental Group · 1 Intervention: Losartan · Intervention Types: Drug
Control GroupNoIntervention Group · 1 Intervention: Control Group · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Losartan
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 90 days post-surgery

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,250 Previous Clinical Trials
743,358 Total Patients Enrolled
Joshua Rozell, MDPrincipal InvestigatorNYU Langone Health

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patients are candidates for elective primary total knee arthroplasty for a diagnosis of osteoarthritis or inflammatory arthritis.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 1st, 2021

Last Reviewed: October 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Washington50.0%
Louisiana50.0%
How old are they?
65+100.0%
What site did they apply to?
NYU Langone Health100.0%
What portion of applicants met pre-screening criteria?
Met criteria50.0%
Did not meet criteria50.0%